Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors

Area of Science:

• Immunology
• Molecular Biology
• Drug Discovery

Background:

• Casitas B-lymphoma proto-oncogene-b (Cbl-b) is an E3 ubiquitin ligase crucial for regulating T-cell function.
• Cbl-b negatively controls T, B, and NK cell activation through ubiquitin-mediated protein modulation.
• Inhibiting Cbl-b ligase activity can enhance immune responses, offering therapeutic potential in immuno-oncology.

Purpose of the Study:

• To discover and optimize novel Cbl-b inhibitors using structure-based drug discovery.
• To identify a potent arylpyridone derivative with therapeutic applications.

Main Methods:

• Structure-based drug discovery approach.
• Optimization of an arylpyridone chemical series.
• Biochemical and cellular assays to assess Cbl-b inhibition and downstream effects.

Main Results:

• Discovery of compound 31, an arylpyridone Cbl-b inhibitor.
• Compound 31 exhibits high binding affinity for Cbl-b (IC50 = 30 nM).
• Compound 31 effectively induces IL-2 production in T-cells (EC50 = 230 nM) and demonstrates target engagement by inhibiting Cbl-b autoubiquitination and ZAP70 ubiquitination.

Conclusions:

• Compound 31 is a potent Cbl-b inhibitor with demonstrated therapeutic potential.
• The identified compound effectively modulates T-cell signaling pathways.
• This discovery advances the development of novel immuno-oncology therapeutics targeting Cbl-b.